ArticleEuropean journal of haematology2019
Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy.
Article in European journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Work Participation of Hematological Cancer Survivors After Hematopoietic Cell Transplantation: A Scoping Review.Journal of occupational rehabilitation · 2026Article
- Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers.Frontiers in oncology · 2026Article
- Different attitudes towards estimating indirect costs of disease: The example of cancer.Journal of public health research · 2025Review
- Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies.Current hematologic malignancy reports · 2025Review
- Management of Multiple Myeloma: A Review for General Practitioners in Oncology.Current oncology (Toronto, Ont.) · 2023Review
- The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma.Bone marrow transplantation · 2021Article
- Perspectives on returning to work of multiple myeloma patients: A qualitative interview study.European journal of cancer care · 2021Article
- Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.Blood cancer journal · 2021Review
- Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2021Article
- Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy.European journal of haematology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveThis study examined productivity losses in European patients with newly diagnosed multiple myeloma (NDMM) undergoing autologous stem cell transplantation (ASCT), to better understand and model the impact of NDMM and lenalidomide maintenance therapy on productivity from a patient and societal perspective.
methodsA cross-sectional online patient survey was conducted across the UK, Germany, France, Spain and Italy. A partitioned survival model was used to estimate productivity loss and the impact of maintenance therapy, using human capital (HC) and friction cost approaches.
resultsOf the 115 eligible survey respondents, 76.5% were economically active at the time of diagnosis and highlighted return to work as an important factor affecting their quality of life; only 39.1% of respondents were economically active post-ASCT. HC analyses estimated average total productivity losses per ASCT patient at EUR 290,601 over a 20-year period. Modelling the impact of maintenance therapy alone for these patients reduced average productivity losses by just over 10%.
conclusionPatients with NDMM aspire to engage in productive lives post-ASCT, but most are unable to do so. Access to treatments extending remission and supporting engagement in a productive life can have a positive impact both for patients and wider society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.